Table 2.

Compares the proportion of respondent answers between geographic regions. Answers are reported in percentages. Far right hand column lists the overall mean and standard deviation, demonstrating the variation between geographic regions

	NA	SA	Aust/NZ	Asia	Europe	Africa	Overall Mean (std)
Majority of patients undergo ovarian reserve testing	61	69	69	83	74	88	74 (10)
AMH testing considered first line	80	41	91	32	71	34	58 (26)
AMH results change stimulation protocol	92	73	92	74	93	87	85 (9)
AMH is considered extremely relevant or relevant	94	80	92	83	90	92	89 (6)
If the AMH test was available in your clinic at no cost, would you use it routinely?	96	79	90	82	89	82	86 (6)
Would you choose AMH above other tests (Age, FSH, AFC, baseline hormones) to assign dosage of gonadotropin?	35	19	72	16	33	13	31 (22)
AMH is the best test for evaluating ovarian reserve	62	43	79	36	53	50	54 (15)
AMH is best used to predict low and high ovarian reserve	82	58	80	63	78	68	72 (10)
AMH is the best predictor of ongoing pregnancy ratesa	3.2	4.6	2.4	4.4	3.6	3.7	4 (1)

NA North America (USA and Canada), SA South America, Aust/NZ Australia and New Zealand, AMH anti-mullerian hormone, FSH follicle stimulating hormone, AFC antral follicle count, std standard deviation

^aOther options were age, FSH, AFC, Other